Drug Database
Back to search

France· FR:68577115

IMJUDO 20 mg/ml, solution à diluer pour perfusion

A tremelimumab product containing trémélimumab, registered in France by ASTRAZENECA AB. The same ATC class is registered in 16 of our 19 countries.

ATC L01FX20

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedIMJUDO 20 mg/ml, solution à diluer po…ATCL01FX20REGISTER NO.FR:68577115PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about trémélimumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tremelimumab is registered in 16 of 19 countries.

Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search tremelimumab products by name

Tremelimumab · ATC L01FX20

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tremelimumab costs, country by country.

Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tremelimumab · price per daily dose (10.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$779.98
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TRÉMÉLIMUMAB
Manufacturer
ASTRAZENECA AB
Country
France (FR)
ATC code
L01FX20
ATC class
Tremelimumab
Defined daily dose
10.7 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955094579
    1 flacon en verre de 15 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tremelimumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tremelimumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Imjudo
  • Liechtenstein · Imjudo
  • Norway · Imjudo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/19f9457d-a6d1-4058-be66-70d070e1cb96
GET /v1/drugs/19f9457d-a6d1-4058-be66-70d070e1cb96?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "68577115",
  "date_amm": "2023-02-20",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/22/1713",
  "substance": "TRÉMÉLIMUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about tremelimumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console